Silence Therapeutics Reports Doubled Net Loss, Near-Total Revenue Collapse, and Key Collaboration Terminations
summarizeSummary
Silence Therapeutics reported a more than doubled net loss and a near-total collapse in revenue for 2025, alongside the termination of key development collaborations with AstraZeneca and Hansoh, significantly impacting its pipeline and future prospects.
check_boxKey Events
-
Net Loss More Than Doubled
The company reported a net loss of $88.6 million for the year ended December 31, 2025, a significant increase from $45.3 million in 2024.
-
Revenue Collapsed
Revenue plummeted to $0.6 million in 2025 from $43.3 million in 2024, primarily due to the conclusion of the Hansoh collaboration and decreased activity with AstraZeneca.
-
AstraZeneca Terminates SLN312 Development
On March 4, 2026, AstraZeneca notified Silence Therapeutics of its decision not to pursue further development of SLN312 beyond Phase 1, leading Silence to regain full global rights to the clinical asset.
-
Hansoh Collaboration Terminated
In December 2024, Hansoh notified Silence Therapeutics that it would not pursue further development under their collaboration, resulting in Silence retaining exclusive global rights for all three targets.
auto_awesomeAnalysis
Silence Therapeutics' annual report reveals a significant deterioration in financial performance for 2025, with net losses more than doubling and revenue collapsing. Critically, two major collaboration agreements were terminated: AstraZeneca will not pursue further development of SLN312 beyond Phase 1, and Hansoh terminated its entire collaboration. These partnership setbacks are substantial blows to the company's pipeline and future revenue potential, indicating a significant shift in its strategic outlook. While the company states its existing cash and short-term investments of $85.1 million are sufficient to fund operations into 2028, this liquidity runway is set against a backdrop of severe operational and financial challenges. The company is actively searching for a new CEO following the departure of its former CEO in December 2025, with the Chairman appointed as Interim Principal Executive Officer.
At the time of this filing, SLN was trading at $5.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273M. The 52-week trading range was $1.97 to $7.78. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.